Angiotensin (1-7) Analog
Also known as: AVE0991, Mas-receptor agonist, Angiotensin-(1-7) analog
Angiotensin (1-7) Analog, also called AVE0991 or Mas-receptor agonist, is a mas receptor agonist in the MasR agonist class. Activates the Mas receptor (ACE2/Ang-(1-7)/Mas axis), opposing AT1-driven vasoconstriction and fibrosis in preclinical cardiovascular models. AVE0991 is a non-peptide Mas agonist used as a research tool.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- Short; orally active analog tested in rodents
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Mas receptor (MAS1)
Research summary
Synthetic Mas-receptor agonist related to angiotensin-(1-7) biology, studied in cardiometabolic and fibrosis models. Not FDA-approved.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studies2 reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Angiotensin (1-7) Analog profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Angiotensin (1-7) Analog dosage: no established human dose
This angiotensin (1-7) analog has no established human dosage. The profile describes a Mas-receptor agonist and names AVE0991, a non-peptide mimic that has only been tested in animals, for example 3 mg/kg a day injected into the abdomen of mice. Human trials exist only for native angiotensin-(1-7), the natural peptide the analog imitates, and they are not evidence for the analog.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: AVE0991 activates the Mas receptor, the receptor for angiotensin-(1-7), and has been studied in rodent models of heart, blood vessel, brain and liver disease, in mg/kg or µmol/kg amounts that do not convert to a human dose. No human study of AVE0991 was found in PubMed or ClinicalTrials.gov. Native angiotensin-(1-7) has been given to people in small cancer and COVID-19 trials, but those doses belong to the natural peptide.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Preclinical — AVE0991 in chronic unpredictable stress in mice (2026)Preclinical · Animal study | Male mice | 3 mg/kg (non-human) | Intraperitoneal | Daily | Last 2 weeks of a 21-day stress protocol | Lower stress hormone and blood glucose, less anxiety- and depression-like behaviour | The nonpeptide angiotensin-(1-7) mimic AVE0991 attenuates neuroendocrine and behavioral responses to chronic unpredictable stress. Psychopharmacology (Berl). 2026. |
| Preclinical — AVE0991 in angiotensin II-induced aortic aneurysm in mice (2020)Preclinical · Animal study | Apolipoprotein E knockout mice | 0.58 or 1.16 µmol/kg a day (non-human) | Not stated in the indexed abstract | Daily | — | Aneurysms in 48% (low dose) and 28% (high dose) versus 76% with vehicle | AVE0991, a nonpeptide angiotensin-(1-7) mimic, inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E knockout mice. J Mol Med (Berl). 2020. |
| Native angiotensin-(1-7), not the analog — phase 1 in advanced cancer (2009)Clinical trial · Phase 1 dose-escalation trial of the parent peptide (analog evidence)Studied an analog, not Angiotensin (1-7) Analog itself | Adults with advanced solid tumours not responding to standard therapy (n=18) | Escalating doses; 400 mcg/kg was the recommended phase 2 dose, and 700 mcg/kg caused dose-limiting stroke and cranial neuropathy | Subcutaneous | Once daily for 5 days in each 3-week cycle | Until disease progression or unacceptable toxicity | One patient had a 19% tumour reduction and three had stable disease beyond 3 months | Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res. 2009. |
| Native angiotensin-(1-7), not the analog — phase 2 in metastatic sarcoma (2016)Clinical trial · Phase 2 trial of the parent peptide (analog evidence)Studied an analog, not Angiotensin (1-7) Analog itself | Adults with metastatic sarcoma (n not stated in the indexed abstract) | 20 mg | Subcutaneous | Daily | — | Well tolerated; median progression-free survival 2.7 months; the biomarker effect seen in phase 1 was not confirmed | Phase II Trial of Angiotensin-(1-7) for the Treatment of Patients with Metastatic Sarcoma. Sarcoma. 2016. |
| Native angiotensin-(1-7), not the analog — COVID-19 in intensive care (2024)Clinical trial · Seamless phase 1-2 randomised trial of the parent peptide (analog evidence)Studied an analog, not Angiotensin (1-7) Analog itself | Adults with COVID-19 pneumonia in intensive care (28 in phase 1, 79 in phase 2) | 5 mcg/kg a day rising to 10 mcg/kg a day after 24 hours (phase 1), or 10 mcg/kg a day (phase 2) | Continuous intravenous infusion | Continuous | Up to 7 days or until ICU discharge | No significant difference in oxygen-free days in phase 2; one bradycardia possibly related to infusion; stopped early for slow recruitment | Angiotensin-(1-7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1-2 randomized clinical trial. Ann Intensive Care. 2024. |
Where sources disagree
- AVE0991 is not a peptide, while angiotensin-(1-7) is a seven-amino-acid peptide. They act on the same receptor, but doses of one are not doses of the other.
- This profile's listed formula, C41H62N12O11, is that of native angiotensin-(1-7), while its synonyms name AVE0991. Products sold under this name may be either compound, which changes what any evidence means for them.
Reconstitution
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Timing Notes
- Explored in hypertension / fibrosis research.
Sequence & molecular data
| Half-life | Short; orally active analog tested in rodents |
|---|---|
| Appearance | White powder (research) |
| Formulation | Lyophilized Powder |
| PubChem CID | 9851724 |
| FDA UNII | 68JR6NCI7I |
| ChEMBL | CHEMBL4303593 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Activates the Mas receptor (ACE2/Ang-(1-7)/Mas axis), opposing AT1-driven vasoconstriction and fibrosis in preclinical cardiovascular models. AVE0991 is a non-peptide Mas agonist used as a research tool.
Origin
Synthetic Mas-receptor agonist (AVE0991 is non-peptide).
Targets
Studies
- The nonpeptide angiotensin-(1-7) mimic AVE0991 attenuates neuroendocrine and behavioral responses to chronic unpredictable stress
- Angiotensin 1-7 and the Non-Peptide MAS-R Agonist AVE0991 Inhibit Breast Cancer Cell Migration and Invasion
- PNA5, a glycosylated angiotensin-(1-7) mas receptor agonist for vascular dementia: A two species toxicology and toxicokinetic study
- PNA5, A Novel Mas Receptor Agonist, Improves Neurovascular and Blood-Brain-Barrier Function in a Mouse Model of Vascular Cognitive Impairment and Dementia
- AVE0991 ameliorates dopaminergic neuronal damage in Parkinson's disease through HOTAIRM1/miR-223-3p/α-synuclein axis
Research statistics
88 PubMed publications · 0.0% human clinical research · 0 registered trials
Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Angiotensin (1-7) Analog is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Angiotensin (1-7) Analog side effects
Angiotensin (1-7) Analog has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Limited human data
- Hypotension possible in models
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Angiotensin (1-7) Analog: frequently asked questions
What is Angiotensin (1-7) Analog?
Synthetic Mas-receptor agonist related to angiotensin-(1-7) biology, studied in cardiometabolic and fibrosis models. Not FDA-approved.
How does Angiotensin (1-7) Analog work?
Activates the Mas receptor (ACE2/Ang-(1-7)/Mas axis), opposing AT1-driven vasoconstriction and fibrosis in preclinical cardiovascular models. AVE0991 is a non-peptide Mas agonist used as a research tool.
Is Angiotensin (1-7) Analog FDA approved?
No. Angiotensin (1-7) Analog is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Angiotensin (1-7) Analog?
Reported half-life for Angiotensin (1-7) Analog is Short; orally active analog tested in rodents. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What peptides are similar to Angiotensin (1-7) Analog?
Compounds most often compared with Angiotensin (1-7) Analog include 5-Amino-1MQ, Adipotide, AICAR and AOD-9604. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- The nonpeptide angiotensin-(1-7) mimic AVE0991 attenuates neuroendocrine and behavioral responses to chronic unpredictable stress — Psychopharmacology (Berl), 2026External reference
- Angiotensin 1-7 and the Non-Peptide MAS-R Agonist AVE0991 Inhibit Breast Cancer Cell Migration and Invasion — Biomedicines, 2025External reference
- PNA5, a glycosylated angiotensin-(1-7) mas receptor agonist for vascular dementia: A two species toxicology and toxicokinetic study — Toxicol Rep, 2025External reference
- PNA5, A Novel Mas Receptor Agonist, Improves Neurovascular and Blood-Brain-Barrier Function in a Mouse Model of Vascular Cognitive Impairment and Dementia — Aging Dis, 2024External reference
- AVE0991 ameliorates dopaminergic neuronal damage in Parkinson's disease through HOTAIRM1/miR-223-3p/α-synuclein axis — Sci Rep, 2024External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 4
This Angiotensin (1-7) Analog profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Angiotensin (1-7) Analog research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →